Store vial at -20° C prior to opening. Aliquot contents and freeze at -20° C or below for extended storage. Avoid cycles of freezing and thawing. Centrifuge product if not completely clear after standing at room temperature. This product is stable for several weeks at 4° C as an undiluted liquid. Dilute only prior to immediate use.
This affinity-purified antibody is directed against the phosphorylated form of human PTEN protein at the pS29 and pT32 residues. Reactivity occurs against human PTEN pS29/pT32 protein and the antibody is specific for the phosphorylated form of the proteins. Approximately 3% reactivity is observed against the non-phosphorylated form of the immunizing peptide. A BLAST analysis was used to suggest cross reactivity with PTEN proteins from mouse and dog sources based on 100% homology with the immunizing sequence. Reactivity against homologues from other sources is not known.
PTEN was identified as a tumor suppressor that is mutated in a large number of cancers at high frequency. The PTEN gene is a phosphatidylinositol-3, 4, 5-trisphosphate 3-phosphatase. It contains a tensin like domain as well as a catalytic domain similar to that of the dual specificity protein tyrosine phosphatases. Unlike most of the protein tyrosine phosphatases, this protein preferentially dephosphorylates phosphoinositide substrates. PTEN negatively regulates intracellular levels of phosphatidylinositol-3, 4, 5-trisphosphate in cells and functions as a tumor suppressor by negatively regulating AKT/PKB signaling pathway. PTEN plays a role as a key modulator of the AKT-mTOR signaling pathway controlling the tempo of the process of newborn neurons integration during adult neurogenesis, including correct neuron positioning, dendritic development and synapse formation. Also, PTEN may be a negative regulator of insulin signaling and glucose metabolism in adipose tissue. The nuclear monoubiquitinated form possesses greater apoptotic potential, whereas the cytoplasmic nonubiquitinated form of PTEN induces less tumor suppressive ability.
For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.
Protein Aliases: homolog of human mutated in multiple advanced cancers; mitochondrial phosphatase and tensin protein alpha; mitochondrial PTENalpha; MMAC1 phosphatase and tensin homolog deleted on chromosome 10; Mutated in multiple advanced cancers 1; Phosphatase and tensin homolog; phosphatase and tensin homolog (mutated in multiple advanced cancers 1); phosphatase and tensin homolog deleted on chromosome ten; phosphatase and tensin-like protein; phosphatidylinositol 3; Phosphatidylinositol 3,4,5-trisphosphate 3-phosphatase and dual-specificity protein phosphatase PTEN; phosphatidylinositol-3; phosphatidylinositol-3,4,5-trisphosphate 3-phosphatase and dual-specificity protein phosphatase PTEN; protein tyrosine phosphatase and tensin-like protein; pten tumor suppressor
Gene Aliases: 10q23del; 2310035O07Rik; A130070J02Rik; AI463227; B430203M17Rik; BZS; CWS1; DEC; GLM2; MHAM; Mmac; MMAC1; PTEN; PTEN1; TEP1